Clinical and pharmacological group: & nbsp
Laxatives
Included in the formulation
АТХ:A.06.A.A.02 Dokazate sodium
Pharmacodynamics:Pharmacological action - a laxative.Reduction of the surface tension in the interaction of the liquid components of the intestinal contents, impregnation of additional feces by the additional liquid to soften them. Anionic surfactant.
When introduced into the rectum, softens the stool and, initiating the defecation reflex, promotes their elimination. The laxative effect develops in 5-20 minutes.
Pharmacokinetics:Absorption is reliably unknown (when ingested - presumably in the gastrointestinal tract). Elimination with feces.
Indications:Symptomatic treatment of constipation, preparation for endoscopic examination of the lower parts of the large intestine.
Removing earwax (cork) - using dokazate sodium and water is just as effective as introducing other specific drugs.
XI.K55-K63.K59.0 Constipation
XXI.Z40-Z54.Z51.4 Preparatory procedures for subsequent treatment, not elsewhere classified
Contraindications:Hypersensitivity, hemorrhoids (in the stage of exacerbation), anus fractures, hemorrhagic proctitis, hemorrhagic colitis. Violation of the patency of the intestine, abdominal pain of unclear etiology.
Carefully:The use is not recommended until age 6 (if ingested - the risk of lipoid pneumonia), the infant solution (inside) is not intended for children up to 6 months,Solutions and capsules for adults are not suitable for children under 12 years.
Pregnancy and lactation:The category of FDA recommendations is not defined. With caution, hypomagnesemia caused by the intake of sodium docusate may lead to hypomagnesemia in the newborn (increased excitability).
Penetrates into breast milk when taken orally, with caution.
Dosing and Administration:The gel is used in the form of a mini-enema, in the composition of one mini-enema is 0.12 g of sodium docusate. Rectally, 5-20 minutes before the expected moment of defecation. Before use, remove the cap from the tip and insert the tip of the tube completely into the anus. Squeeze out the contents of the tube, after which, without stopping the pressure, remove the tube. If necessary, repeat the procedure.
For oral administration, the dose for adults is 300-500 mg per day, for children - 150 mg per day in divided doses.
Side effects:Ingestion: rarely - diarrhea, nausea, abdominal cramps, skin rash, abdominal pain, throat irritation.
For rectal administration: burning in the rectum; with long-term treatment rarely - congestion in the rectum.
Overdose:Not described. Treatment is symptomatic.
Interaction:With simultaneous ingestion docusate facilitates the absorption of other drugs from the digestive tract, which can lead to an increase in their activity and, possibly, toxic action.
With simultaneous use with acetylsalicylic acid, the incidence of side effects of acetylsalicylic acid on the part of the gastrointestinal tract increases.
Dantron, paraffin liquid - Increase in absorption, the risk of toxic effects, damage to the liver with repeated administration, not taken together.
Potassium-sparing diuretics, potassium preparations - the antagonism of action.
Special instructions:Not suitable for long-term use. In case of ineffectiveness of one-two-fold application replace with another laxative.
Do not use together with liquid paraffin.
Can be used as an antiseptic solution for topical application in combination with chlorhexidine bigluconate, chlorobutanol, chloroform.